HSP90-Dependent Nanoparticles Boost CD8+ T Cell Immunity in Foot-and-Mouth Disease

Study Background and Research Question

Foot-and-mouth disease (FMD) continues to pose a significant threat to livestock worldwide, impacting animal health and causing substantial economic losses. While current FMD vaccines effectively induce antibody-mediated (humoral) immunity, they fall short in stimulating robust CD8+ T cell responses and mucosal protection, both of which are crucial for viral clearance and long-term immunity. The central research question addressed by Lv et al. (2026) is whether engineered nanoparticles can facilitate efficient antigen cross-presentation through an Hsp90-dependent pathway, thereby enhancing both cellular and mucosal immune responses against FMDV.

Key Innovation from the Reference Study

The pivotal innovation in this study is the design of HACC-TNF-α-VLP nanoparticles, which combine a chitosan derivative (HACC) with tumor necrosis factor-α (TNF-α) and virus-like particles (VLPs) derived from FMDV. These nanoparticles are engineered to optimize size, charge, and antigen encapsulation for uptake by dendritic cells and subsequent cross-presentation. Critically, the mechanism of action is rooted in the facilitation of antigen presentation via heat shock protein 90 (Hsp90), a molecular chaperone previously implicated in immune modulation and now directly harnessed for vaccine delivery purposes.

Methods and Experimental Design Insights

The research team synthesized HACC-TNF-α-VLP nanoparticles using ionic cross-linking, achieving spherical particles with an average diameter of ~162.7 nm and a zeta potential of −11.9 mV. Encapsulation efficiency reached 84.40%, with a drug loading rate of 12.82%. The nanoparticles demonstrated sustained antigen release, with approximately 75.83% cumulative release over four days. Cytotoxicity was assessed in L929 fibroblasts, showing no toxicity at concentrations ≤400 μg/mL.

In vitro, the nanoparticles were co-cultured with murine bone marrow-derived dendritic cells (BMDCs). Flow cytometry (FCM) and cytokine array analyses quantified dendritic cell maturation and activation. Laser confocal microscopy and FCM were also employed to track nanoparticle uptake and antigen cross-presentation. For in vivo evaluation, mice received nanoparticles via intranasal or subcutaneous immunization. Immune responses were assessed using serum antibody ELISAs, lymphocyte proliferation assays, immunohistochemistry, and FCM to quantify CD8+ T cell responses and mucosal immunity indicators such as secretory IgA.

Protocol Parameters

• Nanoparticle preparation: Ionic cross-linking method, achieving ~162.7 nm size, −11.9 mV zeta potential.
• Encapsulation efficiency: 84.40%, with 12.82% antigen drug loading.
• Cytotoxicity assessment: ≤400 μg/mL, non-toxic to L929 cells.
• In vitro immune stimulation: Co-culture with BMDCs, FCM and cytokine profiling for maturation and activation.
• In vivo immunization: Intranasal or subcutaneous administration in mice; antibody and T cell responses measured by ELISA and FCM.

Core Findings and Why They Matter

The nanoparticles promoted dendritic cell maturation and increased the efficiency of antigen endocytosis and cross-presentation, which was shown to be dependent on Hsp90 activity. Mechanistically, Hsp90 facilitates the processing and presentation of exogenous antigens through MHC class I molecules, activating cytotoxic CD8+ T cells—a pathway typically underutilized by conventional VLP vaccines. As a result, mice immunized with HACC-TNF-α-VLP nanoparticles exhibited significantly elevated levels of FMDV-specific CD8+ T cells, tissue-resident memory T cells, mucosal secretory IgA, and systemic IgG antibodies, as reported in the original article. This dual enhancement of cellular and mucosal immunity addresses a major limitation of current FMD vaccine strategies and suggests a pathway toward more effective, cross-protective vaccines.

Comparison with Existing Internal Articles

Previous research into Hsp90 inhibitors, such as Radicicol, has elucidated the role of Hsp90 in immune modulation, cell cycle regulation, and apoptosis. For instance, internal reviews on Radicicol highlight its ability to downregulate adipogenic transcription factors and enhance apoptosis in cancer models, as well as its relevance in inflammation and sepsis inflammation models. While these studies focus on the inhibitory and regulatory potential of Hsp90 modulators in metabolic and cancer contexts, the current FMDV study leverages Hsp90's chaperone function to promote immune activation via cross-presentation. This demonstrates the context-specific versatility of Hsp90 targeting: inhibition can block pathological signaling pathways (e.g., in cancer or inflammation), while engagement can amplify antigen presentation and vaccine efficacy.

Notably, the reference study’s focus on nanoparticle-mediated enhancement of Hsp90-dependent cross-presentation creates a compelling parallel with assays such as the 3T3-L1 preadipocyte differentiation assay and apoptosis enhancer workflows in ovarian carcinoma, where modulation of Hsp90 function yields distinct cellular outcomes. This highlights the broader relevance of Hsp90 as a molecular switch in diverse research areas—from antiviral immunity to metabolic disease.

Limitations and Transferability

Despite these promising results, several limitations should be considered. The study’s in vivo work was limited to murine models; translational applicability to livestock, the natural FMDV host, remains to be validated. Additionally, while Hsp90-dependent cross-presentation was demonstrated as a key mechanism, the interplay with other antigen processing pathways or host factors is not fully elucidated. The use of VLPs also circumvents the risk of reversion to virulence but may not wholly recapitulate the immunogenicity of live virus exposure.

Transferability to other viral or non-viral pathogens will likely depend on the ability to encapsulate and present relevant antigens efficiently and to ensure that the nanoparticle platform is compatible with the immunological landscape of the target species. Nonetheless, the mechanistic insights provided here lay the groundwork for applying similar strategies in other vaccine development contexts.

Why this cross-domain matters, maturity, and limitations

This study bridges the domains of molecular immunology and nanomedicine by leveraging a well-characterized protein folding chaperone, Hsp90, to solve a pressing vaccine design problem. While the functional versatility of Hsp90 is well documented in oncology and metabolic research, its direct exploitation to improve antigen cross-presentation is a relatively novel application. The maturity of this approach is still at the preclinical, proof-of-concept stage, requiring further validation in target species and eventual field trials. Nonetheless, the findings expand the repertoire of nanoparticle-based adjuvant systems and highlight the importance of cross-domain mechanistic thinking in translational research.

Research Support Resources

For researchers aiming to dissect Hsp90-dependent pathways or to model immune modulation in vitro, chemical biology tools like Radicicol (SKU A4067) are available from APExBIO. As a potent Hsp90 inhibitor, Radicicol can be integrated into workflows examining antigen cross-presentation, apoptosis mechanisms (including the caspase-8 and Bid-dependent apoptosis pathway), and inflammation models—complementing advanced immunological assays such as those used in this study. Protocols for Radicicol use, including preparation and storage, can be found in the product dossier. This supports reproducible research into nanoparticle immunomodulation and Hsp90 function.